Literature DB >> 27089890

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited.

Cesar Luiz Boguszewski1, John Ayuk2.   

Abstract

Based on experimental and animal models, epidemiological data from non-acromegaly populations, and longitudinal and cross-sectional cohorts of patients with acromegaly, a potential association between acromegaly and cancer has long been hypothesized, in particular colorectal cancer, and, to a lesser extent, breast, thyroid and prostate cancers. The exact mechanisms underlying this potential association have not been fully elucidated. Results from studies examining cancer incidence and mortality in acromegaly have been inconsistent, with some demonstrating increased risk, whereas others show no increase. This article reviews the existing data relating to cancer risk and mortality in acromegaly, exploring the limitations of study designs and the impact of changes in disease control and patient outcomes over time.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2016        PMID: 27089890     DOI: 10.1530/EJE-16-0178

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

Review 1.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Predictors of colonic pathologies in active acromegaly: single tertiary center experience.

Authors:  Raim Iliaz; Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Bilger Cavus; Mine Gulluoglu; Filiz Akyuz; Sema Yarman
Journal:  Wien Klin Wochenschr       Date:  2018-07-30       Impact factor: 1.704

Review 3.  The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research.

Authors:  Sofiya Milman; Derek M Huffman; Nir Barzilai
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

4.  Pituitary neuroendocrine tumors and differentiated thyroid cancer: do metabolic and inflammatory risk factors play roles?

Authors:  G Cortês Nascimento; A G P de Araujo Cortês Nascimento; C de Maria Ribeiro Veiga Parente; V P Rodrigues; R S de Sousa Azulay; V C de Carvalho Rocha; S da Silva Pereira Damianse; M Magalhães; M Dos Santos Faria; M B Gomes
Journal:  J Endocrinol Invest       Date:  2020-07-17       Impact factor: 4.256

Review 5.  Acromegaly: clinical features at diagnosis.

Authors:  Lucio Vilar; Clarice Freitas Vilar; Ruy Lyra; Raissa Lyra; Luciana A Naves
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  A permissive role of growth hormone (GH) in the development of second brain tumors after radiotherapy?

Authors:  Pia Burman; Olaf M Dekkers
Journal:  Endocrine       Date:  2017-05-18       Impact factor: 3.633

Review 7.  Cost-effectiveness of acromegaly treatments: a systematic review.

Authors:  Letícia P Leonart; Helena H L Borba; Vinicius L Ferreira; Bruno S Riveros; Roberto Pontarolo
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 8.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

Review 9.  Acromegaly and ultrasound: how, when and why?

Authors:  M Parolin; F Dassie; R Vettor; P Maffei
Journal:  J Endocrinol Invest       Date:  2019-09-09       Impact factor: 4.256

Review 10.  Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.

Authors:  Jaime Guevara-Aguirre; Camila Bautista; Carlos Torres; Gabriela Peña; Carolina Guevara; Cristina Palacios; Alexandra Guevara; Antonio W D Gavilanes
Journal:  Rev Endocr Metab Disord       Date:  2020-10-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.